Clinical trials: sponsored by Boehringer Ingelheim
Lung Diseases, Interstitial
INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
The primary objective of this observational study is to investigate the correlation between changes from baseline at 52 weeks in forced vital capacity (FVC) and changes from baseline at 52 weeks in dyspnea score points or cough…
- Trial name
- INREAL (NCT04702893)
- Testing
- Nintedanib
- Where
- 21 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Overweight, Obesity
A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body
This study is open to Chinese adults aged 18 to 60 with overweight or obesity. People can join the study if they have a Body Mass Index from 24 to 40.0 kg/m2.
- Trial name
- NCT06492135
- Testing
- survodutide
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Empa PASS on Urinary Tract Malignancies
The aim of the study is to assess the risk of urinary tract malignancies in patients initiating empagliflozin (free or fixed dose combination) compared to patients initiating a dipeptidyl peptidase-4 (DPP-4) inhibitor.
- Trial name
- NCT03464045
- Testing
- empagliflozin, DPP-4 inhibitors
- Where
- 3 sites in Finland, Sweden and 1 more
- Volunteers
- 344,995 people
- Sponsor
- Boehringer Ingelheim
Asthma
Characteristics of Pts Initiating Spiriva Respimat in Asthma
This study is a cross-sectional, non-interventional study based on existing data (NISed).
- Trial name
- NCT03692676
- Testing
- Spiriva Respimat
- Where
- Germany
- Volunteers
- 116,133 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood
This study is open to women with overweight or obesity who are otherwise healthy. Women with a body mass index (BMI) from 27 to 40 kg/m2 can participate.
- Trial name
- NCT05896384
- Testing
- BI 456906, Microgynon®
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
To evaluate the safety and tolerability of afatinib (Giotrif) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s) and have never been treated with an EGFR-TKI
- Trial name
- NCT01853826
- Testing
- Afatinib
- Where
- 118 sites in Australia, Austria and 9 more
- Volunteers
- 481 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test How Well Different Doses of BI 3802876 Are Tolerated
The main objective of this trial is to investigate the safety, tolerability, and pharmacokinetics of BI 3802876 when administered in different doses in healthy male volunteers.
- Trial name
- NCT06081530
- Testing
- BI 3802876
- Where
- Belgium
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How BI 1358894 Affects the Way the Body Breaks Down Midazolam
The primary objective of the trial is to investigate the safety and tolerability of BI 1358894 in healthy male subjects following oral administration of multiple rising doses over 14 days.
- Trial name
- NCT03754959
- Testing
- BI 1358894, Midazolam
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test How BI 1358894 is Taken up in the Body and How Food Influences the Amount of BI 1358894 in the Blood
The main objective of Part 1 of this trial is to investigate the absolute bioavailability of BI 1358894 with an intravenous microdose formulation containing labelled [C-14] BI 1358894 and an unlabelled oral tablet formulation of…
- Trial name
- NCT04426851
- Testing
- BI 1358894, BI 1358894 (C-14) intravenous solution
- Where
- Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Gastrointestinal Neoplasms, Cholangiocarcinoma
A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer
Phase 1a - Explore safety and establish the maximum tolerated dose (MTD)/recommended dose levels for phase Ib expansion phase of BI 905711 based on the frequency of patients experiencing dose limiting toxicities (DLTs) during the…
- Conditions
- Gastrointestinal Neoplasms, Cholangiocarcinoma, Pancreatic Neoplasms
- Trial name
- NCT04137289
- Testing
- BI 905711
- Where
- 18 sites in United States, Belgium and 6 more
- Volunteers
- 110 people
- Sponsor
- Boehringer Ingelheim
Healthy
This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood
The primary objective of this trial is to investigate the safety and tolerability of BI 1358894 in healthy male subjects following oral administration of single rising doses.
- Trial name
- NCT03210272
- Testing
- BI 1358894, BI 1358894 (Test), BI 1358894 (Reference)
- Where
- Germany
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test Whether BI 1358894 Reduces Druginduced Panic Symptoms
The main objective of this trial is to investigate the pharmacodynamic effects of a single dose of BI 1358894 on CCK-4- induced anxiogenic/ panic-like symptoms using the PSS in preselected CCK-4 sensitive healthy volunteers.
- Trial name
- NCT03904576
- Testing
- BI 1358894
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Colorectal Cancer
A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery
This study is open to people with newly diagnosed colorectal cancer. People who are scheduled for surgery can participate. People either get a medicine called BI 765063 combined with ezabenlimab or combined with pembrolizumab in…
- Trial name
- NCT05446129
- Testing
- Ezabenlimab, BI 765063, Pembrolizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Boehringer Ingelheim
Obesity
A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity
The main objective of this trial is to investigate the effect of BI 1820237 alone, BI 456906 alone, combination of BI 1820237 and BI 456906 versus placebo on brain activity.
- Trial name
- NCT06352424
- Testing
- BI 456906, BI 1820237
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Fibrosis
A Study in People With Pulmonary Fibrosis to Monitor Cough With a Wearable Device
This study is open to adults aged 18 years and older who have pulmonary fibrosis with or without a known cause (or other forms of pulmonary fibrosis).
- Trial name
- NCT05670587
- Testing
- A wearable cough monitoring device, the Strados Labs RESPᵀᴹ sensor, with an accompanying mobile application (App) for data collection
- Where
- 13 sites in United States, Belgium and 2 more
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Psoriasis
A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis
This study is open to adults with plaque psoriasis. The main purpose of this study is to find out whether people with plaque psoriasis can tolerate a medicine called BI 765250.
- Trial name
- NCT05728489
- Testing
- BI 765250
- Where
- 5 sites in Bulgaria, Georgia and 2 more
- Volunteers
- 64 people
- Sponsor
- Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)
The objectives of this trial are to estimate the following in Japanese patients with advanced NSCLC of stage IIIB/IV or with recurrence after failure of first-line chemotherapy.
- Trial name
- NCT00979576
- Testing
- BIBF 1120 M + Pemetrexed, BIBF 1120 H + Pemetrexed, BIBF 1120 RD + Pemetrexed
- Where
- 3 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
Depressive Disorder, Major
A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression
This study is open to adults with depression (major depressive disorder) for whom standard treatment with antidepressants alone does not work sufficiently.
- Trial name
- NCT04521478
- Testing
- BI 1358894, Quetiapine
- Where
- 120 sites in United States, Argentina and 12 more
- Volunteers
- 389 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test Whether BI 1815368 Influences the Amount of Metformin in the Body
The main objective of this trial is to investigate the effect on the exposure of metformin in plasma when administered as an oral multiple dose together with multiple oral doses of BI 1815368 (Test, T) as compared to when…
- Trial name
- NCT06655220
- Testing
- Metformin hydrochloride, BI 1815368
- Where
- Germany
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Non-squamous, Non-Small Cell Lung Cancer
The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer
This study aims to observe the sequential strategy with afatinib as first-line treatment and to find the optimal treatment strategy for long-term chemotherapy-free regimens in Chinese patients with EGFR-mutated advanced NSCLC.
- Trial name
- NCT04206787
- Testing
- Afatinib
- Where
- 10 sites in China
- Volunteers
- 72 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.